$NIO
NIO Stock Continues Two-Week Rally — How Is ES9 Driving Momentum?
- The stock gained over 3% this week, marking its second consecutive week in the green.
stocktwits.com/news-articles/…
$XOM
-Cowen lowers ExxonMobil target to $172 from $175
Buy
-
$ZNTL
-Guggenheim raises Zentalis Pharmaceuticals target to $10 from $6 on ovarian cancer drug data
-Reiterates Buy rating
m.investing.com/news/analyst-r…
--
$WMB
-Jefferies raises Williams Companies target to $83 from $81
Buy
-
$WSR
-Colliers downgrades Whitestone REIT to Neutral from Buy
Raises target to $19 from $17
-Citizens JMP downgrades to Market Perform from Market Outperform
-
$VRTX
-Morgan Stanley raises Vertex Pharmaceuticals target to $612 from $596
Overweight
-
$WAB
-JPMorgan lowers Wabtec target to $280 from $290
Neutral
-
$WAY
-Bank of America lowers Waystar target to $38 from $45
Buy
-
$WCN
-JPMorgan raises Waste Connections target to $195 from $187
Overweight
-
$VEEV
-Citi downgrades Veeva Systems to Neutral from Buy
Lowers target to $176 from $291
-
$VIK
-Barclays lowers Viking target to $76 from $77
= Weight
-
$VIRT
-Morgan Stanley raises Virtu Financial target to $39 from 436
Underweight
-
$VOYA
-Keefe Bruyette lower Voya Financial target to $81 from $82
Outperform
-Wells argo lowers target to $80 from $85
= Weight
-
$URGN
-Jefferies initiates UroGen Pharma coverage with a Buy rating
$40 target
-
$URI
-JPMorgan lowers United Rentals target to $850 from $970
Overweight
-
$UTHR
-Raymond James initiates United Therapeutics coverage at Outperform
$700 target
-Morgan Stanley raises target to $519 from $471
= Weight
-
$TU
-Scotiabank downgrades TELUS to Sector Perform from Sector Outperform
Lowers target to C$21.50 from C$23
-
$TYL
-BTIG lowers Tyler Technologies target to $420 from $470
Buy
-
$UNM
-Wells Fargo lowers Unum target to $99 from $102
Overweight
-
$TEX
-JPMorgan lowers Terex target to $60 from $76
Neutral
-
$TRI
-Barclays lowers Thomson Reuters target to $170 from $210
Overweight
-
$TROW
-Evercore raises T. Rowe Price target to $99 from $96
In-Line
-BMO lowers target to $98 from $104
Market Perform
-
$STX
-Mizuho raises Seagate target to $565 from $475
Outperform
-Susquehanna raises target to $485 from $400
Neutral
-
$STZ
-UBS raises Constellations Brands target to $186 from $176
Buy
-Citi raises target to $185 from $175
Buy
-Needham raises target to $185 from $180
Buy
-Wells Fargo raises target to $185 from $180
Overweight
-RBC maintains $185 target
Outperform
-Morgan Stanley raises target to $183 from $160
= Weight
-Evercore raises target to $175 from $170
Outperform
-Barclays raises target to $170 from $151
= Weight
-Piper Sandler raises target to $160 from $146
Neutral
-Deutsche Bank raises target to $155 from $154
Hold
-Bank of America raises target to $154 from $142
Underperform
-
$SON
-UBS lowers Sonoco target to $59 from $62
Neutral
-
$SPCE
-Susquehanna raises Virgin Galactic target to $3 from $2.50
Neutral
-
$SPIR
-Canaccord raises Spire target to $22 from $14
Buy
-
$STC
-Keefe Bruyette lower Stewart Information target to $78 from $82
Outperform
-
$SMWB
-Citi downgrades SimilarWeb to Neutral from Buy
Lowers target to $3 from $8.50
-
$SNDK
-Mizuho raises Sandisk target to $1000 from $710
Outperform
-
$SO
-Citi raises Southern Company target to $114 from $107
Buy
-Barclays raises target to $99 from $88
= Weight
-
$SMPL
-DA Davidson reiterates Simply Good Foods $39 target
Buy
-Stifel lowers target to $20 from $32
Buy
-Morgan Stanley lowers target to $14 from $24
= Weight
-Stephens lowers target to $14 from $24
Downgrades to = Weight from Overweight
-Cowen lowers target to $13 from $20
Hold
-Deutsche Bank lowers target to $13 from $16
Hold
-UBS lowers target to $13 from $16
Neutral
$SKLZ
-Cantor initiates Skillz coverage at Overweight
-
$SLGN
-UBS lowers Silgan target to $46 from $50
Neural
-
$SLM
-RBC lowers SLM target to $28 from $32
Outperform
-
$SLP
-Cowen lowers Simulations Plus target to $16 from $19
Hold
-
$SHEL
-Cowen lowers Shell target to $110 from $112
Buy
-
$SHW
-Wells Fargo downgrades Sherwin-Williams to = Weight from Overweight
Lowers target to $365 from $410
-
$SITE
-UBS downgrades SiteOne Landscaping to Neutral from Buy
Lowers target to $140 from $182
-
$ABBV
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
stocktitan.net/news/ABBV/abb-…